Ramsay Générale de Santé SA

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: FR0000044471
EUR
9.26
-0.02 (-0.22%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Ramsay Générale de Santé SA stock-summary
stock-summary
Ramsay Générale de Santé SA
Pharmaceuticals & Biotechnology
Ramsay Generale de Sante SA, formerly Generale de Sante SA (GDS), is a France-based company engaged in the provision of private hospital healthcare services. The Company offers a range of hospital services and, in partnership with independent medical specialists, delivers a spectrum of care services, including oncology and radiation therapy; care for alcohol abuse and obesity; rehabilitation, such as cardiac rehabilitation and orthopedic and neurological reeducation, and diagnostics, such as medical imaging and analysis. In addition, the Company develops a care package, offering care with personal support, before, during and after hospitalization. The Company operates approximately 75 centers and institutions in France. The Company operates through a number of subsidiaries, such as HPM Hopital Prive Metropole SAS. Ramsay Health Care (UK) Ltd is the major shareholder of the Company.
Company Coordinates stock-summary
Company Details
39 Rue Mstislav Rostropovitch , PARIS None : 75017
stock-summary
Tel: 33 1 87862300
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Pascal Roche
Chairman of the Board, Chief Executive Officer
Lorenzo Pellicioli
Vice Chairman of the Board
Dr. Alessandro Bertani
Director
Mr. Paolo Ceretti
Director
Mr. Carlo Frau
Director
Matthias Leridon
Director - Permanent Representative of Sante Europe Participations
Mr. Ross McInnes
Director - Permanent Representative of Sante Europe Investissements
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
448 Million
(Quarterly Results - Dec 2014)
Net Profit:
-5 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

EUR 996 Million ()

stock-summary
P/E

32.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

1.61

stock-summary
Return on Equity

2.87%

stock-summary
Price to Book

0.87